TABLE 6.
EFFICACY OF TREATMENT AT NINE MONTHS, STRATIFIED BY DIOPTRIC GROUP: MULTICENTER CONDUCTIVE KERATOPLASTY (CK ) STUDY
| 8 SPOTS | 16 SPOTS | 24 SPOTS | 32 SPOTS | |
|---|---|---|---|---|
| CRSE RANGE FOR NUMBER OF SPOTS | ||||
| GROUP | 0.75 – 0.875 D | 1.00 – 1.625 D | 1.75 – 2.25 D | 2.375 – 3.00 D |
| UCVA ≤ 20/20 | 7/14 (50%) | 80/140 (57%) | 53/122 (43%) | 32/74 (43%) |
| UCVA ≤ 20/25 | 11/14 (79%) | 109/140 (78%) | 81/122 (66%) | 53/74 (72%) |
| UCVA ≤ 20/40 | 13/14 (93%) | 133/140 (95%) | 109/122 (89%) | 69/74 (93%) |
| MRSE ± 0.50 D | 13/14 (93%) | 97/140 (69%) | 69/122 (57%) | 43/74 (58%) |
| MRSE ± 1.00 D | 14/14 (100%) | 130/140 (93%) | 105/122 (86%) | 55/74 (74%) |
| MRSE ± 2.00 D | 14/14 (100%) | 139/140 (99%) | 119/122 (98%) | 73/74 (99%) |
CRSE = cycloplegic refractive spherical equivalent; MRSE = manifest refractive spherical equivalent; UCVA = uncorrected visual acuity.